



## Financial Tear Sheet

### Corporate Profile

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA<sup>®</sup> ER, NUCYNTA<sup>®</sup>, Gralise<sup>®</sup>, Cambia<sup>®</sup>, Lazanda<sup>®</sup> and Zipsor<sup>®</sup>. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential. Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform<sup>®</sup>, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed's products:

**NUCYNTA<sup>®</sup> ER** (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

**NUCYNTA<sup>®</sup>** (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

**Gralise<sup>®</sup>** (gabapentin), a once-daily product for the management of postherpetic neuralgia,

**Cambia<sup>®</sup>** (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

**Lazanda<sup>®</sup>** (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

**Zipsor<sup>®</sup>** (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for [Gralise](#) and the black box warnings for [NUCYNTA ER](#), [NUCYNTA](#), [Cambia](#), [Lazanda](#) and [Zipsor](#).

### Stock Performance

#### DEPO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$5.90</b>
Change (%)	<b>▼ 0.02 (0.34%)</b>
Volume	810,698
52 Week Low	\$5.81
Market Cap	\$371,635,017
Rolling EPS	-1.79
PE Ratio	N/A
Shares Outstanding	62,988,986



## Recent Headlines

09/05/17

Depomed to Present at the Morgan Stanley Global Healthcare Conference

08/28/17

Depomed to Join the Collaborative for Effective Prescription Opioid Policies to Advance Strategies Aimed at Addressing the Abuse of Opioids

08/07/17

Depomed Announces Second Quarter 2017 Financial Results

## Upcoming Events

There are currently no events scheduled.

## Ownership Summary

### TOP HOLDERS

	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	8,341,874	13.2	-20,933	06/30/17
Senvest Management, LLC	5,605,105	8.9	205,100	06/30/17
Starboard Value LP	5,295,270	8.4	0	07/17/17
The Vanguard Group, Inc.	4,333,107	6.9	-458,093	06/30/17
Armistice Capital LLC	4,050,000	6.4	1,618,000	08/08/17
State Street Global Advisors (US)	2,334,978	3.7	-39,937	06/30/17
Dimensional Fund Advisors, L.P.	2,306,318	3.7	1,063,868	06/30/17
Oak Ridge Investments, LLC	2,299,002	3.7	-83,407	06/30/17
Litespeed Management LLC	2,292,318	3.6	458,620	06/30/17
Discovery Group I, LLC	1,658,826	2.6	1,658,826	06/30/17

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed